Preliminary Study of Curative Effect of Rosiglitazone and Metformin in Women with Polycystic Ovarian Syndrome

Objective: To compare the clinical efficacy of Rosiglitazone and Metformin on insulin action, hirsutism and anovulatory infertility in women with polycystic ovarian syndrome (PCOS) and clomiphene citrate (CC) resistance. Methods: 80 PCOS subjects were randomized to Rosiglitazone group (40 cases) and Meformin group (40 cases). Rosiglitazone and Metformin were respectively administered for 6 months in combining with CC on the 5～9th day of the menstrual cycle. The clinical features, reproductive hormone, serum glucose and insulin levels were observed before and after treatment. The data were analyzed using repeated analysis of variance (ANOVA). Results: After treatment, there was significantly reduction in the hirsutism score, serum LH and testosterone level, and LH/FSH ratio in Metformin group and Rosiglitazone group(both P0.05), and restoration of ovarian ovulation improved in two groups also. Insulin sensitivity has significantly been improved in the Rosiglitazone group compared to Metformin group (P0.05) after treatment. Homa IR and Homaβ were decreased more in Rosiglitazone. Mean BMI was decreased more in Metformin group than in Rosiglitazone group (P0.05). Conclusions: Rosiglitazone improves insulin sensitivity better but Metformin reduces BMI better. They all restore regular menstrual cycles, increase pregnancy rate, and decrease serum testosterone and LH concentration in women with polycystic ovarian syndrome accompanied CC resistance.